Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100930 · ClinicalTrials.gov registry record · NA
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
A NA study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT02100930 is a NA study of Neuroblastoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 69 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02100930, a NA study of Neuroblastoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.
Conditions Studied
Interventions
- BIOLOGICAL Anti-GD2 3F8 Monoclonal Antibody
- DRUG GM-CSF (granulocyte-macrophage colony-stimulating factor)
- DRUG oral isotretinoin
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100930
The ClinicalTrials.gov registry entry for NCT02100930 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Anti-GD2 3F8 Monoclonal Antibody is the first listed.
NCT02100930 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02100930 about?
NCT02100930 is a clinical study titled "Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma". The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.
What is the current status of trial NCT02100930?
This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2014-03. Estimated completion is 2019-03-07.
What conditions does trial NCT02100930 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02100930?
The interventions under investigation include: Anti-GD2 3F8 Monoclonal Antibody (BIOLOGICAL), GM-CSF (granulocyte-macrophage colony-stimulating factor) (DRUG), oral isotretinoin (DRUG).
Who is sponsoring clinical trial NCT02100930?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02100930 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
ACTIVE NOT RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.